Treatment adherence
ALICE pillbox app RCT
Open access · cc by · source: Europe PMC
A Spanish tablet pillbox app improved self-reported adherence and reduced missed doses over 3 months in older adults on multiple medicines.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Multiple studies in this library examine treatment adherence with empirical patient or population outcomes rather than opinion alone.
Evidence for the claim as stated.
Adherence scores rose 28.3% and missed doses fell 27.3% with ALICE; among those with ≥2 prior errors, medication errors fell 41.2%. Clinical labs did not meaningfully improve in 3 months.
Evidence for the claim as stated.
Effect sizes and settings differ across treatment adherence studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Effect sizes and settings differ across treatment adherence studies — digital vs clinic, trial vs observational — so results should not be pooled casually.
- Supports · Does wireless BP monitoring boost patient activation’s benefits?
- Supports · Join2move usage drop-off
Study at a glance
- Design
- RCT — 3-month ALICE tablet reminder vs no app
- N
- N=99 · 48 control, 51 experimental
- Population
- Older multimorbid outpatients on multiple medications in Spanish primary care
- Outcome
- MMAS-4 adherence, missed doses, and medication errors at 3 months
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
ALICE pillbox app RCT
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
99 patients analyzed (48 control, 51 experimental).
Data were obtained from 99 patients (48 and 51 in the control and experimental groups, respectively).
Treatment adherence increased 28.3% and missed doses fell 27.3%.
Specifically, treatment adherence (measured by the scale scores) increased by 28.3% and the rate of missed doses fell by 27.3%.
Key findings
Adherence scores rose 28.3% and missed doses fell 27.3% with ALICE; among those with ≥2 prior errors, medication errors fell 41.2%. Clinical labs did not meaningfully improve in 3 months.
Methodology
After co-design with patients and clinicians, investigators randomized older multimorbid outpatients to 3 months of ALICE tablet reminders versus no app, measuring MMAS-4 adherence, missed doses, and errors.
Limitations
Short follow-up and self-report limits prove hard clinical benefit or generalizability beyond Spanish primary care.
Related papers in this topic
Same topic cluster — not a recommendation engine.